Harvard Bioscience

Harvard Bioscience, Inc.
Public
Traded as NASDAQ: HBIO
Industry Life Science
Founded 1901
Headquarters 84 October Hill Road Holliston, MA 01746, United States
Revenue $105.57 million
Website http://www.harvardbioscience.com/

Harvard Bioscience, Inc. is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research.

Headquartered in Holliston, Massachusetts, United States, the company has 20 wholly owned subsidiaries. Brands include: AHN Biotechnologie, Biochrom, BioDrop, BTX, CMA, Coulbourn Instruments, Denville Scientific, Harvard Apparatus, HEKA, Hoefer, Hugo Sachs Elektronik, Multichannel Systems, Panlab, Scie-Plas, and Warner Instruments.[1]

History

Harvard Bioscience was founded in 1901. Frustrated by the poor quality of equipment then available, Dr. William T. Porter began manufacturing his own high quality physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day. His equipment gained an enviable reputation for quality and reliability and began to be known simply as the Harvard Apparatus.

In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering in December 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.[2]

Products

Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.[3]

Finance

The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%.[4] The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.[5] On November 13, 2013, Harvard Bioscience Inc. announced its allocation of tax basis for spin-off of Harvard Apparatus Regenerative Technology.[6]

References

Notes
  1. ↑ "Company Profile".
  2. ↑ "Company History".
  3. ↑ "Our Technologies".
  4. ↑ "Company Profile of Revenue Results".
  5. ↑ "Company Financial Results".
  6. ↑ "Wall Street Journal News". The Wall Street Journal. November 13, 2013.
This article is issued from Wikipedia - version of the 8/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.